2.4 Cell recognition and the immune system

Question 1

What is an antigen?

Answer 1

● Foreign molecule / protein / glycoprotein / glycolipid

● That stimulates an immune response leading to production of antibody

Question 2

How are cells identified by the immune system?

Answer 2

● Each type of cell has specific molecules on its surface (cell-surface membrane / cell wall) that identify it

● Often proteins → have a specific tertiary structure (or glycoproteins / glycolipids)

Question 3

What types of cells and molecules can the immune system identify?

Answer 3

1. Pathogens (disease causing microorganisms) eg. viruses, fungi, bacteria
2. Cells from other organisms of the same species (eg. organ transplants)
3. Abnormal body cells eg. tumour cells or virus-infected cells
4. Toxins (poisons) released by some bacteria

Question 4

Describe phagocytosis of pathogens (non-specific immune response)

Answer 4

1 - Phagocyte attracted by chemicals / recognises (foreign) antigens on pathogen

2 - Phagocyte engulfs pathogen by surrounding it with its cell membrane

3 - Pathogen contained in vesicle / phagosome in cytoplasm of phagocyte

4 - Lysosome fuses with phagosome and releases lysozymes (hydrolytic enzymes)

5 - Lysozymes hydrolyse / digest pathogen

Question 5

What does phagocytosis lead to?

Answer 5

Phagocytosis leads to presentation of antigens where antigens are displayed on the phagocyte cell-surface membrane, stimulating the specific immune response (cellular and humoral response)

Question 6

Diagram for phagocytosis

Answer 6

Question 7

Describe the response of T lymphocytes to a foreign antigen (the cellular
response)

Answer 7

T lymphocytes recognise (antigens on surface of) antigen presenting cells eg. infected cells, phagocytes presenting antigens, transplanted cells, tumour cells etc.

Specific helper T cells with complementary receptors (on cell surface) bind to antigen on antigen-presenting cell → activated and divide by mitosis to form clones which stimulate:
● Cytotoxic T cells → kill infected cells / tumour cells (by producing perforin)
● Specific B cells (humoral response - see below)
● Phagocytes → engulf pathogens by phagocytosis

Question 8

Describe the response of B lymphocytes to a foreign antigen (the humoral
response)

Answer 8

B lymphocytes can recognise free antigens eg. in blood or tissues, not just antigen presenting cells.
1. Clonal selection:
○ Specific B lymphocyte with complementary receptor (antibody on cell surface) binds to antigen
○ This is then stimulated by helper T cells (which releases cytokines)
○ So divides (rapidly) by mitosis to form clones

2. Some differentiate into B plasma cells → secrete large amounts of (monoclonal) antibody
3. Some differentiate into B memory cells → remain in blood for secondary immune response

Question 9

Diagram for the response of B lymphocytes

Answer 9

Question 10

What are antibodies?

Answer 10

● Quaternary structure proteins (4 polypeptide chains)

● Secreted by B lymphocytes eg. plasma cells in response to specific antigens

● Bind specifically to antigens forming antigen-antibody complexes

Question 11

Describe the structure of an antibody

Answer 11

Question 12

Explain how antibodies lead to the destruction of pathogens

Answer 12

● Antibodies bind to antigens on pathogens forming an antigen-antibody complex
○ Specific tertiary structure so binding site / variable region binds to complementary antigen

● Each antibody binds to 2 pathogens at a time causing agglutination (clumping) of pathogens

● Antibodies attract phagocytes

● Phagocytes bind to the antibodies and phagocytose many pathogens at once

Question 13

Explain the differences between the primary & secondary immune response

Answer 13

● Primary - first exposure to antigen
○ Antibodies produced slowly & at a lower conc.
○ Takes time for specific B plasma cells to be stimulated to produce specific antibodies
○ Memory cells produced

● Secondary - second exposure to antigen
○ Antibodies produced faster & at a higher conc.
○ B memory cells rapidly undergo mitosis to produce many plasma cells which produce specific antibodies

Question 14

What is a vaccine?

Answer 14

● Injection of antigens from attenuated (dead or weakened) pathogens

● Stimulating formation of memory cells

Question 15

Explain how vaccines provide protection to individuals against disease

Answer 15

1. Specific B lymphocyte with complementary receptor binds to antigen
2. Specific T helper cell binds to antigen-presenting cell and stimulates B cell
3. B lymphocyte divides by mitosis to form clones
4. Some differentiate into B plasma cells which release antibodies
5. Some differentiate into B memory cells
6. On secondary exposure to antigen, B memory cells rapidly divide by mitosis to produce B plasma cells
7. These release antibodies faster and at a higher concentration

Question 16

Explain how vaccines provide protections for populations against disease

Answer 16

● Herd immunity - large proportion of population vaccinated, reducing spread of pathogen
○ Large proportion of population immune so do not become ill from infection
○ Fewer infected people to pass pathogen on / unvaccinated people less likely to come in contact with someone with disease

Question 17

Describe the differences between active and passive immunity

Answer 17

• Active immunity requires an initial exposure to antigen eg. vaccine or primary infection whereas passive immunity needs no exposure to antigen
• Memory cells involved in active immunity whereas no memory cells involved
• Active immunity antibody produces and secretes by B plasma cells whereas in passive immunity antibodies are introduced from another organism eg. breast milk / across placenta from mother
• Active immunity is slow; takes longer to develop whereas passive immunity is faster acting
• Active immunity is long term immunity as antibody can be produced in response to a specific antigen again whereas passive immunity is short term immunity as antibody hydrolysed (endo/exo/dipeptidases)

Question 18

Explain the effect of antigen variability on disease and disease prevention

Answer 18

● Antigens on pathogens change shape / tertiary structure due to gene mutations (creating new strains)

● So no longer immune (from vaccine or prior infection)
○ B memory cell receptors cannot bind to / recognise changed antigen on secondary exposure
○ Specific antibodies not complementary / cannot bind to changed antigen

Question 19

Describe the structure of a HIV particle

Answer 19

Question 20

Describe the replication of HIV in helper T cells

Answer 20

1. HIV attachment proteins attach to receptors on helper T cell
2. Lipid envelope fuses with cell-surface membrane, releasing capsid into cell
3. Capsid uncoats, releasing RNA and reverse transcriptase
4. Reverse transcriptase converts viral RNA to DNA
5. Viral DNA inserted / incorporated into helper T cell DNA (may remain latent)
6. Viral protein / capsid / enzymes are produced
   a. DNA transcribed into HIV mRNA
   b. HIV mRNA translated into new HIV proteins
7. Virus particles assembled and released from cell (via budding)

Question 21

Explain how HIV causes the symptoms of acquired immune deficiency
syndrome (AIDS)

Answer 21

● HIV infects and kills helper T cells (host cell) as it multiplies rapidly
○ So T helper cells can’t stimulate cytotoxic T cells, B cells and phagocytes
○ So B plasma cells can’t release as many antibodies for agglutination & destruction of pathogens

● Immune system deteriorates → more susceptible to (opportunistic) infections

● Pathogens reproduce, release toxins and damage cells

Question 22

Explain why antibiotics are ineffective against viruses

Answer 22

Viruses do not have structures / processes that antibiotics inhibit:

● Viruses do not have metabolic processes (eg. do not make protein) / ribosomes
● Viruses do not have bacterial enzymes / murein cell wall

Question 23

What is a monoclonal antibody?

Answer 23

● Antibody produced from genetically identical / cloned B lymphocytes / plasma cells

● So have same tertiary structure

Question 24

Explain how monoclonal antibodies can be used in medical treatments

Answer 24

● Monoclonal antibody has a specific tertiary structure / binding site / variable region

● Complementary to receptor / protein / antigen found only on a specific cell type (eg. cancer cell)

● Therapeutic drug attached to antibody

● Antibody binds to specific cell, forming antigen-antibody complex, delivering drug

Question 25

Explain how monoclonal antibodies can be used in medical diagnosis

Answer 25

● Monoclonal antibody has a specific tertiary structure / binding site / variable region ● Complementary to specific receptor / protein / antigen associated with diagnosis ● Dye / stain / fluorescent marker attached to antibody ● Antibody binds to receptor / protein / antigen, forming antigen-antibody complex

Question 26

Explain the use of antibodies in the ELISA (enzyme-linked immunosorbent assay) test to detect antigens - Example method 1 (direct ELISA):

Answer 26

1. Attach sample with potential antigens to well 2. Add complementary monoclonal antibodies with enzymes attached → bind to antigens if present 3. Wash well → remove unbound antibodies (to prevent false positive) 4. Add substrate → enzymes create products that cause a colour change (positive result)

Question 27

Explain the use of antibodies in the ELISA (enzyme-linked immunosorbent assay) test to detect antigens - Example method 2 (sandwich ELISA):

Answer 27

1. Attach specific monoclonal antibodies to well 2. Add sample with potential antigens, then wash well 3. Add complementary monoclonal antibodies with enzymes attached → bind to antigens if present 4. Wash well → remove unbound antibodies (to prevent false positive) 5. Add substrate → enzymes create products that cause a colour change (positive result)

Question 28

Explain the use of antibodies in the ELISA test to detect antibodies - Example method (indirect ELISA):

Answer 28

1. Attach specific antigens to well 2. Add sample with potential antibodies, wash well 3. Add complementary monoclonal antibodies with enzymes attached → bind to antibodies if present 4. Wash well → remove unbound antibodies 5. Add substrate → enzymes create products that cause a colour change (positive result)

Question 29

Suggest the purpose of a control well in the ELISA test

Answer 29

● Compare to test to show only enzyme causes colour change ● Compare to test to show all unbound antibodies have been washed away

Question 30

Suggest why failure to thoroughly wash the well can result in a false positive in the ELISA test

Answer 30

● Antibody with enzyme remains / not washed out ● So substrate converted into colour product

Question 31

Discuss some general ethical issues associated with the use of vaccines and monoclonal antibodies

Answer 31

● Pre-clinical testing on / use of animals - potential stress / harm / mistreatment ○ But animals not killed & helps produce new drugs to reduce human suffering ● Clinical trials on humans - potential harm / side-effects ● Vaccines - may continue high risk activities and still develop / pass on pathogen ● Use of drug - potentially dangerous side effects

Question 32

Suggest some points to consider when evaluating methodology relating to the use of vaccines and monoclonal antibodies

Answer 32

● Was the sample size large enough to be representative? ● Were participants diverse in terms of age, sex, ethnicity and health status? ● Were placebo / control groups used for comparison? ● Was the duration of the study long enough to show long-term effects? ● Was the trial double-blind (neither doctor / patient knew who was given drug or placebo) to reduce bias?

Question 33

Suggest some points to consider when evaluating evidence and data relating to the use of vaccines and monoclonal antibodies

Answer 33

● What side effects were observed, and how frequently did they occur? ● Was a statistical test used to see if there was a significant difference between start & final results? ● Was the standard deviation of final results large, showing some people did not benefit? ● Did standard deviations of start & final results overlap, showing there may not be a significant difference? ● What dosage was optimum? Does increasing dose increase effectiveness enough to justify extra cost? ● Was the cost of production & distribution low enough?